SCHEMBL31401293

SCHEMBL31401293

CSc1cc(C(=O)O)ccc1Cl

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 3/20 0.59
MAPT P10636 2/20 0.49
ALDH1A1 P00352 1/20 0.49
AR P10275 1/20 0.47
SRD5A2 P31213 1/20 0.47
SMN1; SMN2 Q16637 2/20 0.44
KMT2A Q03164 1/20 0.44
ALOX15 P16050 1/20 0.43
TDP1 Q9NUW8 1/20 0.41
POLB P06746 2/20 0.41
HSD17B10 Q99714 1/20 0.41
TP53 P04637 1/20 0.41
CA12 O43570 2/20 0.41
CA1 P00915 2/20 0.41
CA2 P00918 2/20 0.41
CA4 P22748 2/20 0.41
CA6 P23280 2/20 0.41
CA7 P43166 2/20 0.41
CA9 Q16790 2/20 0.41
CA14 Q9ULX7 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8725872 1.00 TSHR (0.59) TSHRMAPTALDH1A1ARSRD5A2
SCHEMBL7759639 0.84 TSHR (0.63) TSHRMAPTALDH1A1SRD5A2SMN1; SMN2
SCHEMBL27554872 0.81 TSHR (0.59) TSHRMAPTALDH1A1SRD5A2SMN1; SMN2
SCHEMBL4476255 0.78 CA12 (0.57) TSHRMAPTALDH1A1ARSMN1; SMN2
SCHEMBL701970 0.78 TAS1R3 (0.50) TSHRMAPTALDH1A1ARSMN1; SMN2
SCHEMBL10453980 0.78 AR (0.49) TSHRMAPTALDH1A1ARSMN1; SMN2
SCHEMBL28154028 0.77 LMNA (0.49) TSHRMAPTALDH1A1ARSMN1; SMN2
SCHEMBL7275002 0.77 CDC25B (0.50) TSHRMAPTALDH1A1ARSMN1; SMN2
SCHEMBL8352471 0.74 TSHR (1.00) TSHRMAPTALDH1A1SRD5A2KMT2A
SCHEMBL371998 0.74 TSHR (1.00) TSHRMAPTALDH1A1SRD5A2KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4739682-A1 1,6-NAPHTHRIDINE COMPOUNDS AS SMARCA2 INHIBITORS USEFUL FOR THE TREATMENT OF SMARCA4 DEFICIENT CANCERS Janssen Pharmaceutica NV (BE) 2026-05-13 EP disclosed
WO-2025008058-A1 1,6-NAPHTHRIDINE COMPOUNDS AS SMARCA2 INHIBITORS USEFUL FOR THE TREATMENT OF SMARCA4 DEFICIENT CANCERS JANSSEN PHARMACEUTICA NV (BE) 2025-01-09 WO disclosed